Literature DB >> 8942496

p53 overexpression in advanced-stage endometrial adenocarcinoma.

M F Kohler1, P Carney, R Dodge, J T Soper, D L Clarke-Pearson, J R Marks, A Berchuck.   

Abstract

OBJECTIVES: Mutation and overexpression of the p53 tumor suppressor gene in endometrial cancers are associated with advanced stage and poor survival. We sought to determine whether p53 overexpression is an independent variable predictive of poor prognosis in advanced endometrial adenocarcinomas. STUDY
DESIGN: Immunohistochemical evaluation was used to examine p53 expression in paraffin blocks from 179 endometrial adenocarcinomas.
RESULTS: p53 overexpression was seen in 35% of cancers and was associated with higher stage (p = 0.004), black race (p < 0.001), higher grade (p = 0.02), lack of hormone replacement (p = 0.04), and older age (p = 0.05). In addition to a higher frequency of p53 overexpression (57% vs 26%), black women had a lower survival rate than white women (p = 0.001), but overexpression was associated with poor survival in both races. After we corrected for hormone use, multivariate analysis revealed that older age (p < 0.001), higher stage (p < 0.001), higher grade (p = 0.01), and p53 overexpression (p = 0.04) were predictive of poor survival.
CONCLUSIONS: Overexpression of p53 in advanced-stage endometrial cancers is an independent variable that is associated with poor survival, occurs more frequently in black women, and may contribute to the racial disparity in survival.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8942496     DOI: 10.1016/s0002-9378(96)70036-4

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  19 in total

Review 1.  Racial and ethnic disparities in cancers of the uterine corpus.

Authors:  O W Stephanie Yap; Roland P Matthews
Journal:  J Natl Med Assoc       Date:  2006-12       Impact factor: 1.798

2.  Racial disparities in young women with endometrial cancer.

Authors:  Barenya Mukerji; Caitlin Baptiste; Ling Chen; Ana I Tergas; June Y Hou; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2018-01-05       Impact factor: 5.482

3.  Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.

Authors:  A S Felix; T M Brasky; D E Cohn; D G Mutch; W T Creasman; P H Thaker; J L Walker; R G Moore; S B Lele; S R Guntupalli; L S Downs; Ci Nagel; J F Boggess; M L Pearl; O B Ioffe; W Deng; D S Miller; L A Brinton
Journal:  Int J Cancer       Date:  2017-11-06       Impact factor: 7.396

4.  Racial disparities in risk of second primary cancers in endometrial cancer patients: Analysis of SEER Data.

Authors:  Ashley S Felix; Faina Linkov; G Larry Maxwell; Camille Ragin; Emanuela Taioli
Journal:  Int J Gynecol Cancer       Date:  2011-02-01       Impact factor: 3.437

5.  The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium.

Authors:  Oluwole Fadare; Katja Gwin; Mohamed M Desouki; Marta A Crispens; Howard W Jones; Dineo Khabele; Sharon X Liang; Wenxin Zheng; Khaled Mohammed; Jonathan L Hecht; Vinita Parkash
Journal:  Mod Pathol       Date:  2013-03-22       Impact factor: 7.842

6.  Racial disparities in recurrence among patients with early-stage endometrial cancer: is recurrence increased in black patients who receive estrogen replacement therapy?

Authors:  G Larry Maxwell; Chunqiao Tian; John I Risinger; Chad A Hamilton; Richard R Barakat
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860

Review 7.  Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States.

Authors:  B Long; F W Liu; R E Bristow
Journal:  Gynecol Oncol       Date:  2013-05-23       Impact factor: 5.482

8.  Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study.

Authors:  John H Farley; Chunqiao Tian; G Scott Rose; Carol L Brown; Michael Birrer; John I Risinger; J Tate Thigpen; Gini F Fleming; Holly H Gallion; G Larry Maxwell
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

9.  Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma.

Authors:  Judicaël Hotton; Mikaël Agopiantz; Agnès Leroux; Claire Charra-Brunaud; Béatrice Marie; Hélène Busby-Venner; Olivier Morel; Jean-Louis Guéant; Jean-Michel Vignaud; Shyue-Fang Battaglia-Hsu; Guillaume Gauchotte
Journal:  Virchows Arch       Date:  2017-12-14       Impact factor: 4.064

10.  P53 and BCL-2 as prognostic markers in endometrial carcinoma.

Authors:  Márcia L M Appel; Maria I Edelweiss; James Fleck; Luis F Rivero; Waldemar A Rivoire; Heleusa I Mônego; Ricardo Dos Reis
Journal:  Pathol Oncol Res       Date:  2008-04-09       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.